메뉴 건너뛰기




Volumn 7, Issue 3, 2016, Pages 3548-3558

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells

Author keywords

Anticancer agent; Biomarkers; Drug repurposing; Lung cancer

Indexed keywords

AURANOFIN; GLYCOGEN SYNTHASE KINASE 3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; PROTEOME; RICTOR; S6 KINASE; THIOREDOXIN REDUCTASE 1; TUBERIN; TUMOR MARKER; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ANTIRHEUMATIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TXNRD1 PROTEIN, HUMAN;

EID: 84962205847     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6516     Document Type: Article
Times cited : (117)

References (58)
  • 1
    • 84920703518 scopus 로고    scopus 로고
    • Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
    • GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117-171.
    • (2015) Lancet , vol.385 , pp. 117-171
  • 3
    • 84899484919 scopus 로고    scopus 로고
    • Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer
    • Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014; 120:1290-1314.
    • (2014) Cancer , vol.120 , pp. 1290-1314
    • Edwards, B.K.1    Noone, A.M.2    Mariotto, A.B.3    Simard, E.P.4    Boscoe, F.P.5    Henley, S.J.6    Jemal, A.7    Cho, H.8    Anderson, R.N.9    Kohler, B.A.10    Eheman, C.R.11    Ward, E.M.12
  • 4
    • 84875404870 scopus 로고    scopus 로고
    • How can attrition rates be reduced in cancer drug discovery?
    • Moreno L, Pearson AD. How can attrition rates be reduced in cancer drug discovery? Expert Opin Drug Discov. 2013; 8:363-368.
    • (2013) Expert Opin Drug Discov , vol.8 , pp. 363-368
    • Moreno, L.1    Pearson, A.D.2
  • 5
    • 84877579534 scopus 로고    scopus 로고
    • Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity
    • Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013; 138:470-484.
    • (2013) Pharmacol Ther , vol.138 , pp. 470-484
    • Ferri, N.1    Siegl, P.2    Corsini, A.3    Herrmann, J.4    Lerman, A.5    Benghozi, R.6
  • 6
    • 73449101512 scopus 로고    scopus 로고
    • Lessons from 60 years of pharmaceutical innovation
    • Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009; 8:959-968.
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 959-968
    • Munos, B.1
  • 12
    • 0021257099 scopus 로고
    • Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis
    • Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs. 1984; 27:378-424.
    • (1984) Drugs , vol.27 , pp. 378-424
    • Chaffman, M.1    Brogden, R.N.2    Heel, R.C.3    Speight, T.M.4    Avery, G.S.5
  • 13
    • 0023695479 scopus 로고
    • The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. A long-term open study
    • Marcolongo R, Mathieu A, Pala R, Giordano N, Fioravanti A, Panzarasa R. The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. A long-term open study. Arthritis Rheumatism. 1988; 31:979-983.
    • (1988) Arthritis Rheumatism , vol.31 , pp. 979-983
    • Marcolongo, R.1    Mathieu, A.2    Pala, R.3    Giordano, N.4    Fioravanti, A.5    Panzarasa, R.6
  • 19
    • 84862282802 scopus 로고    scopus 로고
    • Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents
    • Schuh E, Pfluger C, Citta A, Folda A, Rigobello MP, Bindoli A, Casini A, Mohr F. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. J Med Chem. 2012; 55:5518-5528.
    • (2012) J Med Chem , vol.55 , pp. 5518-5528
    • Schuh, E.1    Pfluger, C.2    Citta, A.3    Folda, A.4    Rigobello, M.P.5    Bindoli, A.6    Casini, A.7    Mohr, F.8
  • 21
    • 84857720818 scopus 로고    scopus 로고
    • Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership
    • Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res. 2012; 72:1055-1058.
    • (2012) Cancer Res , vol.72 , pp. 1055-1058
    • Weir, S.J.1    DeGennaro, L.J.2    Austin, C.P.3
  • 23
    • 0021927358 scopus 로고
    • Cancer in rheumatoid arthritis: a prospective long-term study of mortality
    • Fries JF, Bloch D, Spitz P, Mitchell DM. Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med. 1985; 78:56-59.
    • (1985) Am J Med , vol.78 , pp. 56-59
    • Fries, J.F.1    Bloch, D.2    Spitz, P.3    Mitchell, D.M.4
  • 26
    • 84898027331 scopus 로고    scopus 로고
    • Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3
    • Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, Wang FS, Wang X. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014; 54:133-146.
    • (2014) Mol Cell , vol.54 , pp. 133-146
    • Wang, H.1    Sun, L.2    Su, L.3    Rizo, J.4    Liu, L.5    Wang, L.F.6    Wang, F.S.7    Wang, X.8
  • 27
    • 33751178410 scopus 로고    scopus 로고
    • The thioredoxin system in cancer
    • Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006; 16:420-426.
    • (2006) Semin Cancer Biol , vol.16 , pp. 420-426
    • Arner, E.S.1    Holmgren, A.2
  • 28
    • 67349120863 scopus 로고    scopus 로고
    • Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions
    • Arner ES. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim Biophys Acta. 2009; 1790:495-526.
    • (2009) Biochim Biophys Acta , vol.1790 , pp. 495-526
    • Arner, E.S.1
  • 29
    • 84872151251 scopus 로고    scopus 로고
    • The biological activity of auranofin: implications for novel treatment of diseases
    • Madeira JM, Gibson DL, Kean WF, Klegeris A. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology. 2012; 20:297-306.
    • (2012) Inflammopharmacology , vol.20 , pp. 297-306
    • Madeira, J.M.1    Gibson, D.L.2    Kean, W.F.3    Klegeris, A.4
  • 30
    • 67650550815 scopus 로고    scopus 로고
    • Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells
    • Wei X, Guo W, Wu S, Wang L, Lu Y, Xu B, Liu J, Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem. 2009; 284:16948-16955.
    • (2009) J Biol Chem , vol.284 , pp. 16948-16955
    • Wei, X.1    Guo, W.2    Wu, S.3    Wang, L.4    Lu, Y.5    Xu, B.6    Liu, J.7    Fang, B.8
  • 31
    • 84863076111 scopus 로고    scopus 로고
    • Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters
    • He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, Wang L, Guo W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS ONE. 2012; 7:e31087.
    • (2012) PLoS ONE , vol.7
    • He, Y.1    Zhou, Z.2    Hofstetter, W.L.3    Zhou, Y.4    Hu, W.5    Guo, C.6    Wang, L.7    Guo, W.8    Pataer, A.9    Correa, A.M.10    Lu, Y.11    Wang, J.12    Diao, L.13
  • 32
    • 78751705649 scopus 로고    scopus 로고
    • The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kB activity
    • Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kB activity. Leukemia Res. 2011; 35:243-249.
    • (2011) Leukemia Res , vol.35 , pp. 243-249
    • Nakaya, A.1    Sagawa, M.2    Muto, A.3    Uchida, H.4    Ikeda, Y.5    Kizaki, M.6
  • 33
    • 84907880426 scopus 로고    scopus 로고
    • Suppression of the pro-inflammatory NLRP3/interleukin-1beta pathway in macrophages by the thioredoxin reductase inhibitor auranofin
    • Isakov E, Weisman-Shomer P, Benhar M. Suppression of the pro-inflammatory NLRP3/interleukin-1beta pathway in macrophages by the thioredoxin reductase inhibitor auranofin. Biochim Biophys Acta. 2014; 1840: 3153-3161.
    • (2014) Biochim Biophys Acta , vol.1840 , pp. 3153-3161
    • Isakov, E.1    Weisman-Shomer, P.2    Benhar, M.3
  • 34
    • 84906249813 scopus 로고    scopus 로고
    • Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth
    • Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, Chen X, Yi S, Xu L, et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014; 5:5453-5471. doi: 10.18632/oncotarget.2113.
    • (2014) Oncotarget , vol.5 , pp. 5453-5471
    • Liu, N.1    Li, X.2    Huang, H.3    Zhao, C.4    Liao, S.5    Yang, C.6    Liu, S.7    Song, W.8    Lu, X.9    Lan, X.10    Chen, X.11    Yi, S.12    Xu, L.13
  • 35
    • 46249116457 scopus 로고    scopus 로고
    • Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia
    • Talbot S, Nelson R, Self WT. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia. Br J Pharmacol. 2008; 154:940-948.
    • (2008) Br J Pharmacol , vol.154 , pp. 940-948
    • Talbot, S.1    Nelson, R.2    Self, W.T.3
  • 38
    • 84876988997 scopus 로고    scopus 로고
    • Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network
    • Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. Clin Genitourin Cancer. 2013; 11:115-120.
    • (2013) Clin Genitourin Cancer , vol.11 , pp. 115-120
    • Vogelzang, N.J.1    Bhor, M.2    Liu, Z.3    Dhanda, R.4    Hutson, T.E.5
  • 41
    • 84857417355 scopus 로고    scopus 로고
    • Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
    • Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012; 109:2718-2723.
    • (2012) Proc Natl Acad Sci USA , vol.109 , pp. 2718-2723
    • Chakrabarty, A.1    Sanchez, V.2    Kuba, M.G.3    Rinehart, C.4    Arteaga, C.L.5
  • 44
    • 84904622446 scopus 로고    scopus 로고
    • Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.[Erratum appears in Invest New Drug. 2014 Jun; 32(3):575]
    • Britten CD, Adjei AA, Millham R, Houk BE, Borzillo G, Pierce K, Wainberg ZA, Lorusso PM. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.[Erratum appears in Invest New Drugs. 2014 Jun; 32(3):575]. Invest New Drugs. 2014; 32:510-517.
    • (2014) Invest New Drugs , vol.32 , pp. 510-517
    • Britten, C.D.1    Adjei, A.A.2    Millham, R.3    Houk, B.E.4    Borzillo, G.5    Pierce, K.6    Wainberg, Z.A.7    Lorusso, P.M.8
  • 46
    • 80455140538 scopus 로고    scopus 로고
    • Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer
    • Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J, Heffron T, Lesnick J, Lewis C, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011; 54:7579-7587.
    • (2011) J Med Chem , vol.54 , pp. 7579-7587
    • Sutherlin, D.P.1    Bao, L.2    Berry, M.3    Castanedo, G.4    Chuckowree, I.5    Dotson, J.6    Folks, A.7    Friedman, L.8    Goldsmith, R.9    Gunzner, J.10    Heffron, T.11    Lesnick, J.12    Lewis, C.13
  • 48
    • 84904720579 scopus 로고    scopus 로고
    • Thioredoxin and glutaredoxinmediated redox regulation of ribonucleotide reductase
    • Sengupta R, Holmgren A. Thioredoxin and glutaredoxinmediated redox regulation of ribonucleotide reductase. World J Biolog Chem. 2014; 5:68-74.
    • (2014) World J Biolog Chem , vol.5 , pp. 68-74
    • Sengupta, R.1    Holmgren, A.2
  • 49
    • 0026715172 scopus 로고
    • Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62
    • Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 1992; 20:3821-3830.
    • (1992) Nucleic Acids Res , vol.20 , pp. 3821-3830
    • Matthews, J.R.1    Wakasugi, N.2    Virelizier, J.L.3    Yodoi, J.4    Hay, R.T.5
  • 51
    • 0029753008 scopus 로고    scopus 로고
    • Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit
    • Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996; 271:32253-32259.
    • (1996) J Biol Chem , vol.271 , pp. 32253-32259
    • Huang, L.E.1    Arany, Z.2    Livingston, D.M.3    Bunn, H.F.4
  • 52
    • 33644818614 scopus 로고    scopus 로고
    • Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine
    • Mitchell DA, Marletta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol. 2005; 1:154-158.
    • (2005) Nat Chem Biol , vol.1 , pp. 154-158
    • Mitchell, D.A.1    Marletta, M.A.2
  • 53
    • 44449119080 scopus 로고    scopus 로고
    • Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins
    • Benhar M, Forrester MT, Hess DT, Stamler JS. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science. 2008; 320:1050-1054.
    • (2008) Science , vol.320 , pp. 1050-1054
    • Benhar, M.1    Forrester, M.T.2    Hess, D.T.3    Stamler, J.S.4
  • 54
    • 55249106018 scopus 로고    scopus 로고
    • The thiol redox state of lymphoid organs is modified by immunization: role of different immune cell populations
    • Castellani P, Angelini G, Delfino L, Matucci A, Rubartelli A. The thiol redox state of lymphoid organs is modified by immunization: role of different immune cell populations. Eur J Immunol. 2008; 38:2419-2425.
    • (2008) Eur J Immunol , vol.38 , pp. 2419-2425
    • Castellani, P.1    Angelini, G.2    Delfino, L.3    Matucci, A.4    Rubartelli, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.